s. sonnei 1790gahb
Vaccineexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02017899)
Timeline
Indications
Mechanism of action
- Shigella sonneiImmunity, active
Shigella sonnei immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- s. sonnei 1790gahb
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02676895 | Phase 2 | Aug 1, 2016 | GlaxoSmithKline |
| NCT02034500 | Phase 1 | Mar 1, 2014 | GlaxoSmithKline, University of London |
| NCT02017899 | Phase 1 | Feb 1, 2014 | GlaxoSmithKline, University of Paris |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 2014 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1